New Trade Deal: India-US Pact's Impact on Medical Devices

The new interim trade agreement framework has significantly reshaped the commercial landscape for the India US Medical Devices sector. As India agrees to ease non-tariff barriers for U.S.-made medical devices, the domestic industry is strongly pushing for reciprocal treatment. This necessary balance ensures fair trade and sustained growth for Indian manufacturers. Consequently, both nations released a joint statement outlining these key changes.

India Eases Non-Tariff Barriers for US Devices

India is committed to eliminating restrictive import licensing procedures which previously delayed market access for U.S. medical devices. This move addresses a long-standing barrier to trade. Furthermore, the statement provides a six-month timeline. Within this window, India will update its stance on accepting U.S.-developed or international standards, including testing requirements, for U.S. exports in identified market sectors. This regulatory harmonization aims to streamline the import process. Himanshu Baid, MD of Poly Medicure Ltd., views this interim agreement as a strong opportunity. Specifically, he highlights the potential for deeper technology collaboration in high-value segments like medical imaging, where US companies possess established strengths.

Reciprocity Demanded by the Domestic Industry

While welcoming the agreement, the Association of Indian Medical Device Industry (AiMeD) Coordinator, Rajiv Nath, seeks reciprocal treatment. Notably, he argues that import licenses for U.S. devices are already processed faster than those for Indian manufacturers. Therefore, Indian firms face mandatory inspections while overseas companies do not. Moreover, trade data shows significant asymmetry. The U.S. leads imports into India at ₹14,000 crore, surpassing China’s ₹12,000 crore, while India's exports stand at approximately $750 million. In addition, the US FDA’s preference for ACSA over NABL labs further exacerbates this asymmetry. Ultimately, the industry wants mutually advantageous trade to empower both nations' innovations.

Lower Tariffs Boost Indian Medical Devices Exports

The U.S. administration already agreed to slash tariffs on Indian medical devices. These tariffs dropped sharply from 50 per cent to 18 per cent under the interim deal. Consequently, this change immediately positions India’s domestic industry below its international competitors, most notably China, which faces a headline tariff rate of 37 per cent. As a result, this tariff reduction acts as a game-changer for Indian manufacturers. It cuts export costs and unlocks billions in the U.S. market, aligning with global supply chain shifts like 'China+1'. With US import tariffs now at 18 per cent, Indian MedTech exporters gain a meaningful competitive advantage in one of the world's most sophisticated healthcare markets. Nevertheless, India still meets 70 per cent of its medical device requirements through imports, highlighting a high dependence due to limited domestic manufacturing capacity for high-end equipment.

Key Trade Segments for India US Medical Devices

The trade predominantly involves distinct types of products. Top imports from the U.S. include sophisticated items. For example, these items include diagnostic reagent kits, linear ultrasound devices, and various software-based devices. Meanwhile, India’s top exports focus on high-volume products. Specifically, these products are items such as bandages, waste disposable bags, and headgears.

Frequently Asked Questions

Q1: What is the primary change for US medical devices entering India?

India agrees to ease non-tariff barriers, specifically eliminating restrictive import licensing procedures that previously delayed market access.

Q2: How does the new trade agreement benefit Indian medical device manufacturers?

The US reduced tariffs on Indian medical devices from 50% to 18%. Therefore, this significantly enhances their competitive advantage in the U.S. market.

Q3: What reciprocal treatment is the Indian medical device industry seeking?

The domestic industry seeks reciprocal fairness in regulatory processes, such as acceptance of NABL labs by the US FDA, to balance the trade asymmetry.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. India-US trade deal: Domestic industry seek reciprocity as India agrees to easeentry for US devices - ETHealthworld


2. India-US trade deal: Domestic industry seek reciprocity as India agrees to ease entry for US devices. indiatimes.com.


3. US-India interim trade deal extends tariff shield for Indian pharma, with riders. livemint.com.


4. India’s generic drug juggernaut was unstoppable amid US tariffs. Why a new trade deal may not change that. indianexpress.com.


5. What India gave the US to seal a $500 billion interim trade deal. economictimes.com.


6. After 10 Months of Tariff Deadlock, US and India Find Common Ground on Trade. india-briefing.com.


7. India-US Trade Deal: Zero tariffs on agri, gems, pharma. deccanherald.com.


8. United States-India Joint Statement. whitehouse.gov.


9. India-U.S. interim trade deal: Closely engaged with America for electronics and IP, Union Minister Vaishnaw says. thehindu.com.


10. India-US trade deal: Interim pact to boost Indian stock markets, over 30 stocks to buy today — 9 February 2026. livemint.com.